Insulet Analyst Price Targets - Benzinga

Insulet Corp

PODDNASDAQ

Trade with Public

Trade with Public

$141.96

0.860.61%

Últ. Act.: Oct 19, 4:00 PM

$141.96

0.860.61%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Insulet Analyst Price Targets

Wall Street analyst price targets and consensus rating for Insulet (PODD).

Price Target Range — 9 Quarters

Analyst Consensus — 23 Analysts

15Buy

8Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$232Upside to Avg. PT+63.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Jefferies	Matthew Taylor	PT Cut	Buy	$275→$190
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Equal-Weight	$150
Aug 6, 2026	Canaccord Genuity	William Plovanic	PT Cut	Buy	$249→$179
Aug 6, 2026	Leerink Partners	Mike Kratky	Downgrade	Outperform→Market Perform	$247→$145
Aug 6, 2026	TD Cowen	Mathew Blackman	PT Cut	Hold	$294→$144
Aug 6, 2026	UBS	Patrick Wood	PT Cut	Neutral	$174→$150
Aug 6, 2026	RBC Capital	Shagun Singh	PT Cut	Outperform	$245→$160
Aug 6, 2026	Bernstein	Lee Hambright	PT Cut	Outperform	$200→$175
Aug 6, 2026	Truist Securities	Richard Newitter	Downgrade	Buy→Hold	$210→$153
Aug 6, 2026	Benchmark	Bruce D. Jackson	PT Cut	Buy	$250→$185
Aug 6, 2026	Stifel	Jonathan Block	PT Cut	Buy	$225→$180
Aug 6, 2026	Wells Fargo	Lawrence Biegelsen	Downgrade	Overweight→Equal-Weight	$255→$144
Aug 6, 2026	JP Morgan	Robbie Marcus	Downgrade	Overweight→Neutral	$275→$152
Aug 6, 2026	BTIG	Marie Thibault	Downgrade	Buy→Neutral	—
Jul 28, 2026	UBS	Patrick Wood	Assumes	Buy→Neutral	$174
Jul 13, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$219→$210
Jul 13, 2026	RBC Capital	Shagun Singh	PT Cut	Outperform	$280→$245
Jul 10, 2026	Stifel	Jonathan Block	PT Cut	Buy	$250→$225
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$165→$172
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$200→$180

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Jefferies Maintains Buy on Insulet, Lowers Price Target to $190

Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $275 to $190.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150

Barclays analyst Christopher Pasquale initiates coverage on Insulet (NASDAQ:PODD) with a Equal-Weight rating and announces Price Target of $150.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179

Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $249 to $179.

Benzinga Newsdesk

PRO
Leerink Partners Downgrades Insulet to Market Perform, Lowers Price Target to $145

Leerink Partners analyst Mike Kratky downgrades Insulet (NASDAQ:PODD) from Outperform to Market Perform and lowers the price target from $247 to $145.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Insulet, Lowers Price Target to $144

TD Cowen analyst Mathew Blackman maintains Insulet (NASDAQ:PODD) with a Hold and lowers the price target from $294 to $144.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Insulet, Lowers Price Target to $150

UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and lowers the price target from $174 to $150.

Benzinga Newsdesk